Hollyhigh International Capital
Global M&A China, founded in 1998, is a leading Chinese investment bank solely specializing in the Pharmaceutical industry with the core businesses of Licensing/M&A/financing advisory, Buy-out funds, Bio-venture funds, PIPE funds, etc… which provides full-service for Pharmaceutical companies.
In 21 years of activity, we have successfully completed more than 220 transactions valued at more than US$ 16 billion. The company currently manages more than USD$ 700 million of asset through two pharmaceutical funds.
The team of Global M&A China consists of professionals from a variety of backgrounds and brings a world of specialized industry experience and personal insights into the businesses. 70% of the team members come from renowned overseas pharmaceutical companies and most of them have Biological or pharmaceutical academic background. They have worked in capital market and pharmaceutical industry since the 90s and gained valuable experience.
Global M&A China trades locally as Hollyhigh International Capital, and has offices in both Beijing and Shanghai.